Monday, July 14, 2008 8:09:44 AM
Monday July 14, 7:40 am ET
Neurogen pauses trial of insomnia drug candidate adipiplon because of next-day effects
BRANFORD, Conn. (AP) -- Biotechnology company Neurogen Corp. said Sunday it stopped a clinical trial of its insomnia candidate adipiplon because of negative side effects.
The Branford, Conn. company is developing immediate-release and controlled-release forms of the drug, and was testing a tablet that combined both versions. Neurogen said the combined drug may not be working as expected, leading to "a higher than anticipated rate of unwanted next day effects" in the phase 2/3 trial.
Patients have received both kinds of adipiplon in previous trials, but this is the first trial of the combination tablet. Neurogen said it will investigate before continuing with the trial.
"We are disappointed by this setback," said Stephen R. Davis, president and chief executive of Neurogen, in a statement. "We do not yet know whether there is a path forward with lower doses of the existing formulation or whether further formulation development would be required."
The company scheduled a conference call to discuss the results at 8:30 a.m Eastern time.
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM